Abstract:Background Cellular cementum (CC) includes cementocytes, cells suspected to regulate CC formation or resorption as osteocytes do in bone. Sclerostin (SOST) is a secreted negative regulator of Wnt/β‐catenin signaling expressed by osteocytes and cementocytes. Osteocyte SOST expression reduces bone formation. We investigated the functional importance of SOST in CC compared with alveolar bone (AB) using a Sost knockout (Sost−/−) mouse model to better understand the role of cementocytes in CC. Methods Mandibles and femurs of Sost−/− and wild‐type (WT) mice were analyzed at 42 and 120 days postnatal (dpn). Maxillary first molars were bilaterally extracted at 42 dpn and both AB healing (maxillary molar sockets) and CC apposition (mandibular first molars) were examined at 21 days post‐procedure. Analyses included micro‐computed tomography, histology, and immunohistochemistry. Results Femur cortical and trabecular bone and mandibular bone volumes were similarly increased in Sost−/− versus WT mice at 42 and/or 120 dpn. In contrast to previous reports, CC was not increased by Sost−/− at either age. We conducted challenge experiments on AB and CC to explore tissue‐specific responses. Post‐extraction AB healing was improved by Sost deletion. In contrast, experimentally‐induced apposition in molars failed to stimulate increased CC formation in Sost−/− versus WT mice. Wnt pathway markers AXIN2 and DKK1, which were increased in Sost−/− versus WT AB osteocytes, were unchanged in cementocytes. Conclusions These data indicate CC is less responsive than AB to SOST deletion. Within the study limitations, these results do not support cementocytes as critical for directing increased CC formation. Plain language summary Sclerostin is a protein known to inhibit bone formation, and removing sclerostin leads to more bone formation. Cementum is the thin layer that covers the surface of the tooth's root. Previous studies suggest that inhibiting sclerostin can similarly increase the amount of cementum. We wanted to compare the response of cementum and bone when sclerostin is absent to understand similarities and differences between these two tissues. In this study, we removed the Sost gene (the gene which produces sclerostin) in mice. We found that mice without sclerostin have more bone in their legs and jaws. Moreover, mice without sclerostin also healed better after tooth removal compared with normal mice. Surprisingly, unlike previous studies, we found that the amount of cementum was not different in mice without sclerostin compared with normal mice. Additionally, we challenged the cementum by taking out the opposing tooth to cause the first mandibular molar to move up by building more cementum. Even with this challenge, we found no difference in the amount of cementum in mice lacking sclerostin compared with normal mice. Therefore, we conclude here that cementum is less sensitive to the absence of sclerostin compared with bone.

Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells

Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats

Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes

PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade

Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats

Sclerostin Inhibition Reverses Systemic, Periarticular and Local Bone Loss in Arthritis

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-mediated Antagonism of Wnt/LRP6 Signaling.

Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone Forming Cells and Their Progenitors through Distinct Mechanisms.

Sclerostin Protects Against Vascular Calcification Development in Mice

Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways

Τhe story of sclerostin inhibition: the past, the present, and the future

Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes

Sclerostin and skeletal health

A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis

Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength

Loss of Nmp4 enhances bone gain from sclerostin antibody administration

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder

Disparate effects of sclerostin deletion on alveolar bone and cellular cementum in mice